E.R. SAGITOVA, G.B. KUCHMA, L.K. KOZLOVA, A.A. PAN’KOVA, E.D. NIKITINA

 Orenburg State Medical University, Orenburg

 Contact details:

Sagitova Elvira Rifkatovna — Ph. D. (medicine), Associate Professor of the Department of Polyclinic Therapy

Address: 6 Sovetskaya St., Orenburg, Russian Federation, 460000, tel.: +7-912-354-53-81, e-mail: sagel.8181@mail.ru

Systemic lupus erythematosus is a complicated autoimmune disease, presenting difficulties both in diagnostics and in the selection of effective therapy. The complexity of the clinical situation consisted in the fact that systemic lupus erythematosus debuted with the development of isolated thrombocytopenia. This caused difficulty in therapy selection, since the use of glucocorticosteroids had only a short-term effect, and thrombopoietin receptor agonists (romiplostim) was prescribed by a Medical Board under unregistered indications.

Key words: systemic lupus erythematosus, immune thrombocytopenia, alopecia, metipred, romiplostim, retuximab.

REFERENCES

1. Petrov A.V., Beloglazov V.A., Gaffarova A.S., Rod’ko E.D., Petrov A.A. Clinical significance of thrombocytopenia in systemic lupus erythematosus, 2018, no. 2, pp. 55–57 (in Russ.), available at: https: //cyberleninka.ru/article/n/klinicheskoe-znachenie-trombotsitopenii-pri-sistemnoy-krasnoy-volchanke
2. Yen E.Y., Singh R.R. Brief report: lupus-an unrecognized leading cause of death in young females: a population-based study using nationwide death certificates, 2000–2015. Arthritis Rheumatol, 2018, vol. 70 (8), pp. 1251–1255.
3. Tsokos G.C. Autoimmunity and organ damage in systemic lupus erythematosus. Nat. Immunol, 2020, vol. 21 (6), pp. 605–614.
4. Fanouriakis A., Bertsias G., Boumpas D.T. Population-based studies in systemic lupus erythematosus: immune thrombocytopenic purpura or “blood-dominant” lupus? Ann Rheum. Dis, 2020, vol. 79 (6), pp. 683–684.
5. Lila V.A. Clinical and laboratory relationships in patients with various variants of the course of systemic lupus erythematosus. Sovremennaya revmatologiya, 2020, vol. 14, no. 1, pp. 26–31 (in Russ.). DOI: 10.14412/1996-7012-2020-1-26-31
6. Costa Pires T., Caparrós-Ruiz R., Gaspar P., Isenberg D.A. Prevalence and outcome of thrombo-cytopeniain systemic lupus erythematosus: single-centre cohort analysis. Clin. Exp. Rheumatol, 2021, vol. 39 (3), pp. 601–605.
7. Roussotte M., Gerfaud-Valentin M., Hot A. et al. Immune thrombocytopenia with clinical signifi-cance in systemic lupus erythematoisus: a retrospective cohort study of 90 patients. Rheumatol. (Oxf. Engl.), 2022, vol. 61 (9), pp. 3627–3639.
8. Jiang Y., Cheng Y., Ma S. et al. Systemic lupus erythematosus-complicating immune throm-bocytopenia: from pathogenesis to treatment. J. Autoimmun, 2022, vol. 132, p. 102887.